-
May 17, 2022 Comparing MindMed, Atai Life Sciences, Compass Pathways: A Psychedelic Stock AnalysisOur resident psychedelic investor explains a handful of important metrics to study when analyzing and...
-
May 14, 2022 MindMed Releases LSD for Anxiety Data ! (MNMD, MMED)Get your 20%-off tickets to the Catalyst Psychedelics Summit in Kingston Ontario, May 20th-23rd: www.eventbrite.ca/e/153409882087/?discount=SPOTLIGHT20...
-
May 13, 2022 Psychedelic Business Spotlight – May 13This week in psychedelic business news: Beckley Retreats set launch; another shark swims into the...
-
May 11, 2022 MindMed’s Phase 2 LSD Trial Treating Anxiety Was a SuccessResearchers at PSYCH Symposium reveal promising results from double-blind, placebo-controlled study with 46 patients.
-
May 10, 2022 Why Wednesday Will Be Biggest Day of 2022 for Psychedelic InvestorsPsychedelic investors are about to see pivotal data presented on flagship programs by the titans...
-
May 10, 2022 Field Trip And Wesana Make Major Moves | FTRP, WESAGet your 20%-off tickets to the Catalyst Psychedelics Summit in Kingston Ontario, May 20th-23rd: www.eventbrite.ca/e/153409882087/?discount=SPOTLIGHT20...
-
May 9, 2022 Five Telling Takeways from Benzinga Psychedelics Capital ConferencePsychedelic Spotlight's video producer attended the inaugural Benzinga Psychedelic Capital Conference, and here's what he...
-
May 6, 2022 Psychedelic Business Spotlight – May 6This week in psychedelic business news: Wesana Health pivots strategy; Compass Pathways makes progress on...
-
May 6, 2022 Wesana Health May Sell Clinics to Focus Solely on Drug Development: An AnalysisWesana Health reaches a major strategic pivot point. Our resident Psychedelic Investor examines what this...
-
May 5, 2022 Compass Pathways Shares ‘Promising’ Data That Psilocybin May Treat AnorexiaThere is currently no FDA-approved treatment for anorexia. Could psychedelics be the answer?
